K. Jensen

Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme

B. Zinman, J. Buse, X. Pi-Sunyer, 2013, Diabetes, obesity & metabolism.

Patient acceptance and issues of education of two durable insulin pen devices.

K. Jensen, T. Asakura, H. Seino, 2008, Diabetes technology & therapeutics.

IncretIn-Based therapy for type 2 dIaBetes: overcomIng unmet needs

K. Jensen, 2012 .

Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program.

M. Davies, J. Buse, R. Pratley, 2011, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Late-Breaking Clinical Trial Report

M. Davies, J. Buse, R. Pratley, 2011 .

iGlarLixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post Hoc Analysis of LixiLan-L

K. Jensen, E. Niemoeller, E. Souhami, 2017, Diabetes Therapy.

Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial

P. Ponikowski, A. Parkhomenko, B. Lewis, 2020, The Lancet.

Comparison of Intuitiveness, Ease of Use, and Preference in Two Insulin Pens

K. Jensen, T. Asakura, 2009, Journal of diabetes science and technology.

A Review of 25 Years’ Experience with the NovoPen® Family of Insulin Pens in the Management of Diabetes Mellitus

K. Jensen, J. Hyllested-Winge, Jørn Rex, 2010, Clinical drug investigation.

A Review of 20 Years’ Experience with the Novopen® Family of Insulin Injection Devices

K. Jensen, Jørn Rex, Klaus H Jensen, 2006, Clinical drug investigation.

Intuitiveness, instruction time, and patient acceptance of a prefilled insulin delivery device and a reusable insulin delivery device in a randomized, open-label, crossover handling study in patients with type 2 diabetes.

Andreas Pfützner, K. Jensen, A. Pfützner, 2008, Clinical therapeutics.

Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program.

M. Davies, J. Buse, R. Pratley, 2011, Endocrine Practice.